Study validates a new risk model that allows for more accurate risk estimates, encourages shared decision-making, and helps ...

Once reserved for very high-risk patients, the use of transcatheter aortic valve replacement in low-risk cases has increased ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. At 7 years, there was no difference in clinical outcomes ...

Please provide your email address to receive an email when new articles are posted on . TAVR did not improve a composite of clinical endpoints in patients with moderate aortic stenosis and HFrEF.

SAN FRANCISCO -- Long-term outcomes after transcatheter aortic valve replacement (TAVR) were looking more and more like those after surgical aortic valve replacement (SAVR) in low-risk patients, ...

Add Yahoo as a preferred source to see more of our stories on Google. Edwards Lifesciences' Sapien 3 Ultra system. The artificial heart valve is pushed through the blood vessels via a catheter and ...

The Co-STAR trial tested the performance of colchicine in preventing new-onset arrhythmias and subclinical leaflet thrombosis after TAVR. The choice of periprocedural treatment with colchicine was ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. Aurora St. Luke’s Medical Center and its team of world ...

In December, Edwards Lifesciences persuaded CMS to publish an updated tracking sheet for TAVR national coverage analysis, causing the agency to reconsider its previous stance on covering transcatheter ...

The heart valve specialist reported a second straight quarter of double-digit TAVR sales growth and credited recent study results with driving a “sense of urgency” for treating patients.